Akademik Veri Yönetim Sistemi
Legal Medicine, cilt.81, 2026 (SCI-Expanded, Scopus)
Objective Medications are frequently reported in association with suicidality in youth, yet age-specific risks within reported cases remain unclear. We aimed to analyze drug-related suicide among children and adolescents in the FDA Adverse Event Reporting System (FAERS). Methods We conducted a retrospective study of FAERS reports from 1997 to 2024 that involved 5–19-year-olds and any suicide-related events. We described demographics and age-/sex-stratified adjusted reporting-odds ratios (aOR) for fatality; a 2014–2024 window confirmed robustness. Results We identified 18,779 cases, most from 13 to 17-years; girls constituted the majority (58.3%) except in the 5–12-years group. Completed-suicide reports accounted for 22.3% overall, rising from 6.9% (5–12 years) to 32.0% (18–19 years). Diphenhydramine showed the highest odds of reported death (aOR 8.2, 95% CI: 6.3–10.7), followed by oxycodone (6.7, 4.7–9.5) and bupropion (5.6, 4.6–6.9), stable in the last-decade subset. Age-dependent increase in reporting odds of death for risperidone (7.4, 3.3–16.5), atomoxetine (3.3, 1.6–7.1), and montelukast (2.8, 1.2–6.3) reversed after 18 years. Fluoxetine and quetiapine were associated with death predominantly in girls, whereas venlafaxine and paroxetine were more prominent in boys. Conclusion Across FAERS youth suicide reports, drug-associated fatality risk varies markedly by drug, surges in mid- to late adolescence, diverges by sex and shifts at both age extremes. These heterogeneities underscore the need for age-appropriate pharmacovigilance and trial strategies rather than direct extrapolation from adult data, particularly regarding the safety of drugs associated with suicide.